Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Interleukin–based therapy for Age-associated dementia and Alzheimer’s disease (AD): IL-6 increases the expression of AGE receptor 1 (AGER1), the longevity-promoting gene Sirtuin-1 and decreases advanced glycation end products (AGEs) via down regulation of its target gene, 12/June/2015, 8.43 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Significance: This study suggests, for the first time, that IL-6, by decreasing the expression of its target gene, it may: (1) increase the expression of AGE receptor 1 (AGER1); (2) increase the expression of longevity-promoting gene Sirtuin-1; and (3) decrease advanced glycation end products (AGEs). Thus, pharmacological formulations encompassing “IL-6 activators” can be used to decrease ageing and increase the life-span of an individual.
Undisclosed information: How IL-6 increases the expression of AGER1
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation